Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR Mersana Therapeutics Inc (0M4.SG) Follow Compare 0.4837 -0.0195 (-3.88%) At close: February 21 at 9:32:08 PM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 0M4.SG 1D 5D -16.75% 1M -9.22% 3M -74.18% 6M -60.50% YTD -65.38% 1Y -85.36% 5Y -94.03% All -87.30% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 0M4.SG View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday? Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... Q3 2024 Mersana Therapeutics Inc Earnings Call Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report Related Tickers A89.F Adocia SA 4.9550 +1.33% ADOC.PA Adocia SA 4.9400 -0.60% SYRS Syros Pharmaceuticals, Inc. 0.1743 -0.85% MRNA Moderna, Inc. 35.53 +5.34%